EIF2A and non-small cell lung carcinoma: To further evaluate whether p-PKR or p-eIF2α protein expression correlates with clinical outcomes of patients with NSCLC, Kaplan–Meier analysis revealed that for stage I and all stages, patients with relatively elevated p-PKR had significantly longer survival than those with little or no p-PKR expression (Figure 3A and 3C).